Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 10/20 | 0.48 |
| ▸ | LPL | P06858 | 9/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | P4HB | P07237 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CA9 | Q16790 | 3/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.37 |
| ▸ | UNG | P13051 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.36 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31390229 | 1.00 | LIPG (0.48) | LIPGLPLALDH1A1P4HBBRD4 | |
| SCHEMBL4757491 | 0.92 | LIPG (0.45) | LIPGLPLALDH1A1P4HBBRD4 | |
| SCHEMBL18479991 | 0.83 | LIPG (0.48) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL1823266 | 0.83 | LIPG (0.48) | LIPGLPLALDH1A1P4HBCA1 | |
| SCHEMBL28791185 | 0.82 | LIPG (0.44) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL20573186 | 0.82 | LIPG (0.44) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL15372954 | 0.81 | LIPG (0.47) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL1476213 | 0.81 | LIPG (0.59) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL3797726 | 0.80 | LIPG (0.40) | LIPGLPLP4HBBRD4CA1 | |
| SCHEMBL20539098 | 0.80 | LPL (0.49) | LIPGLPLP4HBCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4565562-B1 | PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | NXERA PHARMA UK LTD (GB) | 2026-05-27 | — | — | EP | disclosed |
| US-20260042745-A1 | PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | NXERA PHARMA UK LIMITED (GB) | 2026-02-12 | — | — | US | disclosed |
| US-12492174-B2 | Morpholine-3-carboxamide derivatives as prostaglandin E2 receptor 4 (EP4) agonists for the treatment of gastrointestinal and pulmonary diseases | NXERA PHARMA UK LIMITED (GB) | 2025-12-09 | — | — | US | disclosed |
| EP-4565562-A1 | PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | Nxera Pharma UK Limited (GB) | 2025-06-11 | — | — | EP | disclosed |
| US-20250179036-A1 | MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | NXERA PHARMA UK LIMITED (GB) | 2025-06-05 | — | — | US | disclosed |
| EP-4532491-A1 | MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | Nxera Pharma UK Limited (GB) | 2025-04-09 | — | — | EP | disclosed |
| WO-2025059074-A1 | BICYCLIC COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| WO-2024263969-A2 | HETEROARYL COMPOUNDS AS ENDOCANNABINOID SYSTEM MODULATORS AND USES THEREOF | NORTHEASTERN UNIVERSITY (US) | 2024-12-26 | — | — | WO | disclosed |
| US-20240409609-A1 | REVERSIBLE LYSINE COVALENT MODIFIERS OF EGFR AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2024-12-12 | — | — | US | disclosed |
| WO-2024028603-A1 | PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-02-08 | — | — | WO | disclosed |
| US-20120252777-A1 | THIAZOLOPYRIMIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-10-04 | — | — | US | disclosed |
| US-20120252777-A1 | THIAZOLOPYRIMIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-10-04 | — | — | US | disclosed |
| US-20120252777-A1 | THIAZOLOPYRIMIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-10-04 | — | — | US | disclosed |
| WO-2012130780-A1 | THIAZOLOPYRIMIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-10-04 | — | — | WO | disclosed |
| US-8084449-B2 | Dual pharmacophores—PDE4-muscarinic antagonistics | GLAXO GROUP LIMITED (GB) | 2011-12-27 | — | — | US | disclosed |
| US-8084449-B2 | Dual pharmacophores—PDE4-muscarinic antagonistics | GLAXO GROUP LIMITED (GB) | 2011-12-27 | — | — | US | disclosed |
| US-20100210627-A1 | PYRAZINE COMPOUNDS, THEIR USE AND METHODS OF PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-19 | — | — | US | disclosed |
| US-20090203657-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| WO-2009100166-A1 | DUAL PHARMACOPHORES-PDE4-MUSCARINIC ANTAGONISTICS | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | WO | disclosed |
| US-20090203657-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042745-A1 | PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | PTGER4, PTGER1, PTGER2 | LIPG 1692/4885LPL 2671/4885ALDH1A1 1803/4885 |
| US-12492174-B2 | Morpholine-3-carboxamide derivatives as prostaglandin E2 receptor 4 (EP4) agonists for the treatment of gastrointestinal and pulmonary diseases | PTGER4, PTGER1, PTGER2 | LIPG 1201/4885LPL 2839/4885ALDH1A1 1720/4885 |
| US-20090203657-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | PDE4A, PDE1A, PDE4B | LIPG 1445/4885LPL 1668/4885ALDH1A1 826/4885 |
| US-20120252777-A1 | THIAZOLOPYRIMIDINE COMPOUNDS | SYK, BTK, ZAP70 | LIPG 4075/4885LPL 4247/4885ALDH1A1 2469/4885 |
| US-20240409609-A1 | REVERSIBLE LYSINE COVALENT MODIFIERS OF EGFR AND USES THEREOF | EGFR, ERBB2, ERBB3 | LIPG 2794/4885LPL 4452/4885ALDH1A1 3648/4885 |
| US-20100210627-A1 | PYRAZINE COMPOUNDS, THEIR USE AND METHODS OF PREPARATION | CDK2, PIM1, CCNK | LIPG 3821/4885LPL 4165/4885ALDH1A1 3122/4885 |
| US-20250179036-A1 | MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | PTGER4, PTGER1, PTGER2 | LIPG 1201/4885LPL 2839/4885ALDH1A1 1720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.